2019最新：全球急性髓性白血病(AML)在研药物一览

【官宣】第二届药融圈CBV（CEO+BD+VC）高峰论坛，最终嘉宾日程曝光！高质量，免费学习交流机会。正文：2019最新：全球急性髓性白血病(AML)在研药物一览，本文来自于最近NRDD论文The acute myeloid leukaemia market。仅供参考。详见：doi:10.1038/d41573-019-00142-4；Nature Reviews Drug Discovery。药物名称公司靶点机制临床进展CrenolanibAROG PharmaceuticalsFLT3 and PDGFRPhase IIIGuadecitabineAstex Pharmaceuticals/Otsuka PharmaceuticalDNA methyltransferasePhase IIIIomab-BActinium PharmaceuticalsCD45Phase IIICC-486CelgeneDNA methyltransferasePhase IIIUproleselanGlycoMimeticsE-selectinPhase IIIDevimistatRafael Pharmaceuticals/Ono PharmaceuticalLipoate analoguePhase IIIIdasanutlinRocheMDM2Phase IIIPevonedistatTakeda OncologyNAEPhase IIIPracinostatHelsinn Healthcare/MEI PharmaHDACPhase IIIAlvocidibTolero Pharmace ………………………………